Английская Википедия:Filorexant
Шаблон:Short description Шаблон:Drugbox
Filorexant (Шаблон:Abbrlink, Шаблон:Abbrlink; developmental code name MK-6096) is an orexin antagonist which was under development by Merck for the treatment of insomnia, depression, diabetic neuropathy, and migraine.[1][2] It is a dual antagonist of the orexin OX1 and OX2 receptors.[3][4] It has a relatively short elimination half-life of 3 to 6Шаблон:Nbsphours.[5] However, it dissociates slowly from the orexin receptors and may thereby have a longer duration.[6] Possibly in relation to this, filorexant shows next-day somnolence similarly to suvorexant.[6] In phase 2 clinical trials, filorexant was found to be effective in the treatment of insomnia,[7] but was not effective in the treatment of major depressive disorder,[8][9][10] painful diabetic neuropathy,[11][12] or migraine.[13] Шаблон:As of, filorexant was no longer listed on Merck's online development pipeline and hence development of the drug appears to have been discontinued.[14][5][1] Development of filorexant may have been discontinued due to lack of differentiation from suvorexant (which was also developed by Merck).[6]
See also
References
External links
Шаблон:Orexin receptor modulators
Шаблон:Nervous-system-drug-stub
- ↑ 1,0 1,1 Шаблон:Cite web
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ 5,0 5,1 Шаблон:Cite journal
- ↑ 6,0 6,1 6,2 Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite book
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite web